AB
ARQT icon

Amalgamated Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Amalgamated Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,458
Closed -$100K – 1706
2025
Q4 		$100K Sell
3,458
-265
-7% -$6.78K ﹤0.01% 1700
2025
Q3 		$70K Hold
3,723
– – ﹤0.01% 1755
2025
Q2 		$52K Hold
3,723
– – ﹤0.01% 1818
2025
Q1 		$58K Buy
3,723
+1,053
+39% +$14.8K ﹤0.01% 1769
2024
Q4 		$37K Hold
2,670
– – ﹤0.01% 1909
2024
Q3 		$25K Hold
2,670
– – ﹤0.01% 2038
2024
Q2 		$25K Hold
2,670
– – ﹤0.01% 2039
2024
Q1 		$26K Sell
2,670
-8,408
-76% -$62.8K ﹤0.01% 2034
2023
Q4 		$36K Buy
11,078
+3,639
+49% +$9.89K ﹤0.01% 2386
2023
Q3 		$40K Hold
7,439
– – ﹤0.01% 2339
2023
Q2 		$71K Buy
7,439
+1,624
+28% +$18K ﹤0.01% 2184
2023
Q1 		$64K Sell
5,815
-797
-12% -$11.5K ﹤0.01% 2202
2022
Q4 		$98K Hold
6,612
– – ﹤0.01% 2142
2022
Q3 		$126K Buy
6,612
+1,079
+20% +$24.4K ﹤0.01% 2042
2022
Q2 		$118K Buy
5,533
+2,074
+60% +$42.5K ﹤0.01% 2097
2022
Q1 		$67K Buy
+3,459
New +$58.5K ﹤0.01% 2331

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Bank's ARQT Position: Q1 2026 in Review

Amalgamated Bank sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 3,458 shares — an estimated $100K sold.

Amalgamated Bank first reported a position in ARQT in Q1 2022 and held it in 16 quarters. The position peaked at $126K in Q3 2022. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Amalgamated Bank reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 3,458 Arcutis Biotherapeutics shares in Q1 2026, an estimated $100K.
  • Amalgamated Bank first reported a position in Arcutis Biotherapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Arcutis Biotherapeutics position peaked at $126K in Q3 2022.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.